- Home
- VYGR vs LYEL Comparison
VYGR vs LYEL Comparison
Compare VYGR & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- LYEL
- Stock Information
- Founded
- VYGR 2013
- LYEL 2018
- Country
- VYGR United States
- LYEL United States
- Employees
- VYGR N/A
- LYEL N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- VYGR Health Care
- LYEL Health Care
- Exchange
- VYGR Nasdaq
- LYEL Nasdaq
- Market Cap
- VYGR 231.9M
- LYEL 253.2M
- IPO Year
- VYGR 2015
- LYEL 2021
- Fundamental
- Price
- VYGR $4.23
- LYEL $17.67
- Analyst Decision
- VYGR Strong Buy
- LYEL Hold
- Analyst Count
- VYGR 7
- LYEL 3
- Target Price
- VYGR $17.00
- LYEL $16.67
- AVG Volume (30 Days)
- VYGR 551.0K
- LYEL 25.1K
- Earning Date
- VYGR 11-06-2025
- LYEL 11-12-2025
- Dividend Yield
- VYGR N/A
- LYEL N/A
- EPS Growth
- VYGR N/A
- LYEL N/A
- EPS
- VYGR N/A
- LYEL N/A
- Revenue
- VYGR $42,580,000.00
- LYEL $60,000.00
- Revenue This Year
- VYGR N/A
- LYEL N/A
- Revenue Next Year
- VYGR $107.10
- LYEL N/A
- P/E Ratio
- VYGR N/A
- LYEL N/A
- Revenue Growth
- VYGR N/A
- LYEL 11.11
- 52 Week Low
- VYGR $2.65
- LYEL $7.65
- 52 Week High
- VYGR $7.44
- LYEL $29.60
- Technical
- Relative Strength Index (RSI)
- VYGR 41.58
- LYEL 59.52
- Support Level
- VYGR $4.10
- LYEL $16.00
- Resistance Level
- VYGR $4.30
- LYEL $17.95
- Average True Range (ATR)
- VYGR 0.26
- LYEL 1.16
- MACD
- VYGR -0.10
- LYEL -0.11
- Stochastic Oscillator
- VYGR 20.89
- LYEL 69.08
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.